Medication info

Prismasol 4 Potassium Solution

Prescription medication
Ingredient · strength
Calcium Chloride Hydrate›0.0257g / 100mLMagnesium Chloride Hydrate›0.0102g / 100mLS-Lactic Acid›0.03g / 100mLGlucose Monohydrate›0.121g / 100mLSodium Chloride›0.6128g / 100mLPotassium Chloride›0.0298g / 100mLSodium Bicarbonate›0.2936g / 100mL
Manufacturer / importer
VANTIVE KOREA INCORPORATED
Appearance
Slightly transparent yellow dialysis filtrate after mixing
Packaging
5000 ml/bag
Approval status
Active

MFDS item code 201702026 · Approved 2017.04.20 · Insurance code 646601721

Summary

Main use
Hemofiltration and dialysis for renal failure; treatment of poisoning by dialyzable substances
Who uses it
Adults · Children
Adult dosage
The dose and rate of administration are determined according to the patient's blood electrolyte concentrations, acid-base balance, fluid balance, and overall clinical condition. The volume of replacement fluid and/or dialysate to be administered is determined according to the desired intensity of treatment (dose). This medicine should be prescribed and administered (dose, infusion rate, and cumulative volume) only by physicians experienced in critical care medicine and continuous renal replacement therapy. Replacement-fluid flow rate during hemofiltration and hemodiafiltration: Adults: 500 - 3000 ml/h Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration: Adults: 500 - 2500 ml/h The flow rate commonly used in adults is approximately 2000 - 2500 mL/h, corresponding to a daily replacement-fluid volume of approximately 48 - 60 L. For intravenous use and as replacement fluid for hemodialysis, administer into the extracorporeal circuit before (pre-dilution) or after (post-dilution) passage through the hemofilter or hemodiafilter.
Children's dosage
Replacement-fluid flow rate during hemofiltration and hemodiafiltration—Children (adolescents 18 years of age or younger): 1000 - 2000 mL/h/1.73 m2 Replacement-fluid flow rate during hemofiltration and hemodiafiltration—particularly in younger children (≤10 kg): a flow rate of up to 4000 mL/h/1.73 m2 may be required. Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration—Children (adolescents 18 years of age or younger): 1000 - 2000 mL/h/1.73 m2 Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration—particularly in younger children (≤10 kg): a flow rate of up to 4000 mL/h/1.73 m2 may be required. The absolute flow rate (mL/h) in children and adolescents should generally not exceed the maximum flow rate for adults.

Ingredients

Importer
VANTIVE KOREA INCORPORATED

Efficacy & effects

Hemofiltration and dialysis for renal failure; treatment of poisoning by dialyzable substances

View approved original text

This medication is used as a fluid substitute during blood filtration and dialysis for patients with renal failure, and is also used as a dialysis solution for continuous blood dialysis or dialysis filtration. Additionally, it helps remove substances that can be dialyzed or filtered in cases of drug overdose. This medication is particularly safe and effective for patients with normal potassium levels, thus assisting in fluid and dialysis management in various situations related to renal failure.

Dosage and Administration

Adult dosage

The dose and rate of administration are determined according to the patient's blood electrolyte concentrations, acid-base balance, fluid balance, and overall clinical condition. The volume of replacement fluid and/or dialysate to be administered is determined according to the desired intensity of treatment (dose). This medicine should be prescribed and administered (dose, infusion rate, and cumulative volume) only by physicians experienced in critical care medicine and continuous renal replacement therapy. Replacement-fluid flow rate during hemofiltration and hemodiafiltration: Adults: 500 - 3000 ml/h Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration: Adults: 500 - 2500 ml/h The flow rate commonly used in adults is approximately 2000 - 2500 mL/h, corresponding to a daily replacement-fluid volume of approximately 48 - 60 L. For intravenous use and as replacement fluid for hemodialysis, administer into the extracorporeal circuit before (pre-dilution) or after (post-dilution) passage through the hemofilter or hemodiafilter.

Children's dosage

Replacement-fluid flow rate during hemofiltration and hemodiafiltration—Children (adolescents 18 years of age or younger): 1000 - 2000 mL/h/1.73 m2 Replacement-fluid flow rate during hemofiltration and hemodiafiltration—particularly in younger children (≤10 kg): a flow rate of up to 4000 mL/h/1.73 m2 may be required. Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration—Children (adolescents 18 years of age or younger): 1000 - 2000 mL/h/1.73 m2 Dialysate flow rate during continuous hemodialysis and continuous hemodiafiltration—particularly in younger children (≤10 kg): a flow rate of up to 4000 mL/h/1.73 m2 may be required. The absolute flow rate (mL/h) in children and adolescents should generally not exceed the maximum flow rate for adults.

Precautions

This medication should not be used in certain patients. For example, it should not be administered to patients who are allergic to this medication or those with high serum potassium levels, or those with metabolic alkalosis. Moreover, it should not be used in patients whose azotemia is not corrected by blood filtration due to renal failure or in cases where arterial pressure is insufficient for vascular access. It should also be avoided in patients undergoing systemic anticoagulation therapy who are at high risk for bleeding. Various adverse reactions may occur during the use of this medication. Metabolic and nutritional-related adverse reactions such as fluid imbalance, electrolyte imbalance, hyperglycemia, and metabolic alkalosis have been reported. Hypotension, nausea, vomiting, and muscle cramps may also occur, thus caution is needed. This medication is used in blood filtration or dialysis treatment for patients with renal failure and must be administered under the supervision of a qualified physician. Serum potassium levels, hemodynamic status, fluid balance, electrolytes, and acid-base balance should be carefully monitored before and during treatment. Phosphate levels and blood sugar levels should be checked periodically, and special attention should be given to blood sugar control in diabetic patients. As this medication contains potassium, if hyperkalemia occurs, administration must be stopped immediately and appropriate measures should be taken to remove potassium if needed. This medication should not be used in patients with corn allergies, and if hypersensitivity reactions occur, administration must be stopped immediately. This medication can interact with other drugs, so dosage adjustments for medications being removed during dialysis may be necessary. Particularly, if sodium bicarbonate or buffers are added, the risk of metabolic alkalosis may increase, and the risk of hypercalcemia may also rise when used with calcium or vitamin D related drugs. There is insufficient safety data for patients who are pregnant or breastfeeding, so the benefits and risks should be carefully considered before administering this medication. In cases of overdose, fluid overload, electrolyte imbalance, and acid-base imbalance may occur, and in such cases, administration must be stopped immediately, and appropriate measures should be taken. Close monitoring during treatment is essential to prevent serious side effects from overdose. This medication must be used only in appropriate equipment and in a sterile environment, and the clarity and sealing status of the solution must be confirmed before administration. The mixed solution should be used immediately, and any remaining solution after use should be discarded. Furthermore, this medication should not be mixed with other drugs, and any mixing must be handled safely per the physician's instructions. During storage, it should be kept in a sealed container to prevent contact with air, and the storage temperature should be maintained between 4 degrees and 30 degrees Celsius. This will help preserve the medication's effectiveness.

Side effects

  • Fluid imbalance
  • dehydration
  • hypophosphatemia
  • hyperglycemia
  • metabolic alkalosis
  • metabolic acidosis
  • hypotension
  • nausea
  • vomiting
  • muscle cramps
Show 2 more
  • fluid overload
  • hypokalemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent contact with air, and the storage temperature must be maintained between 4 degrees and 30 degrees Celsius. This will help maintain the medication's efficacy.

Appearance and packaging

Appearance

Slightly transparent yellow dialysis filtrate after mixing

Package unit

5000 ml/bag

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.